Research chemicalResearch chemicalDissociativeArylcyclohexylamine

3-MeO-PCP

Also known as 3-MeO-PCP · 3-Methoxyphencyclidine

Written by enwyReviewed 4 Aug 20262 sources0 comments

3-MeO-PCP is a potent arylcyclohexylamine dissociative and PCP analogue sold as a research chemical. It is notably stimulating and has a narrow margin of safety, with a well-documented risk of overdose, agitation and stimulant-type psychosis. It has been implicated in multiple hospitalisations and deaths.

01 Overview

3-MeO-PCP is one of the more potent and long-lasting dissociatives available on the research-chemical market. Compared with ketamine it is more stimulating and less anaesthetic, with users reporting a manic, energetic character. Its potency and the small difference between an active and an excessive dose make accidental overdose common.

Human data are limited to case reports and analytical toxicology. Overdose presents with agitation, hypertension, tachycardia, hyperthermia and psychosis; catatonia and prolonged dissociation have also been reported. Its psychosis risk and narrow therapeutic-to-toxic margin make it one of the higher-risk novel dissociatives.

02 Mechanism

Potent NMDA-receptor antagonist with additional affinity for serotonin and dopamine transporters, contributing to its stimulating and psychosis-inducing profile.

03 Dosing

Tier	Dose	Route	Notes
Threshold	2–5 mg	Oral
Common	4–10 mg	Insufflated
Common	5–15 mg	Oral	Narrow margin; small increases raise overdose risk sharply.

04 Effects

Effect	Magnitude	Evidence
Stimulating dissociationEnergetic, manic dissociation distinct from the sedating character of ketamine.		Anecdotal
AnalgesiaReported pain relief typical of NMDA antagonists.		Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence	Countermeasures
Overdose (narrow margin)Tachycardia, hypertension, hyperthermia and severe agitation; the small gap between active and toxic doses makes overdose easy.	Life-threatening	Common at high doses	Observational
Psychosis and agitationParanoia, delusions and stimulant-type psychosis, sometimes prolonged.	Severe	Common at higher doses	Observational

06 Legal status

United States

Possibly controlled as a PCP analogue

May fall under the Federal Analogue Act. · as of Jan 2026

United Kingdom

Class B controlled drug

Controlled as an arylcyclohexylamine. · as of Jan 2026

07 References

3-MeO-PCP: analytical and clinical case reportsPubMed literature

New psychoactive substances: dissociativesEUDA (European Union Drugs Agency)

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.